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ABSTRACT 
 Epigallocatechin gallate (EGCG) is the 
principal bioactive ingredient in green tea and 
has been reported to have many health benefits. 
EGCG influences multiple signal transduction 
pathways related to human diseases, including 
redox, inflammation, cell cycle, and cell 
adhesion pathways. However, the molecular 
mechanisms of these varying effects are unclear, 
limiting further development and utilization of 
EGCG as a pharmaceutical compound. Here, 
we examined the effect of EGCG on two 
representative transmembrane signaling 
receptors, integrin αIIbβ3 and epidermal 
growth factor receptor (EGFR). We report that 
EGCG inhibits talin-induced integrin αIIbβ3 
activation, but it activates αIIbβ3 in the absence 
of talin both in a purified system and in cells. 
This apparent paradox was explained by the 
fact that the activation state of αIIbβ3 is tightly 
regulated by the topology of β3 transmembrane 
domain (TMD); increases or decreases in TMD 
embedding can activate integrins. Talin 
increases the embedding of integrin β3 TMD 
resulting in integrin activation, whereas we 
observed here that EGCG decreases it, thus 
opposing talin-induced integrin activation. In 
the absence of talin, EGCG decreases the TMD 
embedding which can also disrupt the integrin 
α-β TMD interaction, leading to integrin 
activation. EGCG exhibited similar paradoxical 
behavior in EGFR signaling. EGCG alters the 
topology of EGFR TMD and activates the 
receptor in the absence of EGF, but inhibits 
EGF-induced EGFR activation. Thus, this 
widely ingested polyphenol exhibits pleiotropic 
effects on transmembrane signaling by 
modifying the topology of TMDs. 
 
 
 Green tea is one of the most popular drinks 
for thousands of years, both as a beverage and as a 
herbal medicine. Indeed, green tea has many 
clinically reported health benefits, including the 
prevention of cardiovascular diseases (1,2) and 
cancer (3). Studies on the beneficial effects of 
green tea using cellular or animal models have 
recently converged on EGCG, the most abundant 
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polyphenol considered as health promoting 
phytonutrient in green tea, and have found EGCG 
to influence multiple signal transduction pathways 
related to antioxidation, inflammation, cell cycle, 
and cell adhesion (4). However, the molecular 
mechanism underlying those effects has remained 
elusive. Although EGCG has been suggested to 
have a number of molecular targets (5), only DNA 
methyltransferase (6) and 67 kDa laminin receptor 
(7) have been demonstrated to directly respond to 
EGCG in an in vitro system. On the other hand, 
recent nuclear magnetic resonance spectroscopy 
studies clearly showed that EGCG can interact 
with model lipid membranes (8,9), which implies 
that biological membrane can be a molecular 
target of EGCG. Furthermore, the EGCG-lipid 
interaction can cause a deformation of the lipid 
bilayer, e.g. by inducing an expansion of the lipid 
bilayer (10) and/or altering the thickness of the 
membrane (11). Since membrane-receptor 
interactions are important in maintaining the 
proper TMD topology, structures, and hence 
function of the transmembrane receptors (12,13), 
chemical and physical alteration in biological 
membrane may cause changes in activities of 
those proteins (14). However, whether such lipid-
EGCG interaction contributes to and how it could 
account for the broad effects of EGCG on many 
cell signaling pathways are yet to be elucidated. 
 We hypothesized that EGCG exerts its effect 
on transmembrane receptor signaling by 
interacting with a lipid bilayer and thereby 
changing the TMD topology and signaling of a 
broad spectrum of transmembrane proteins. We 
tested this hypothesis using integrin αIIbβ3 and 
EGFR, two prototypical signaling receptors. 
Integrin αIIbβ3 is a heterodimeric transmembrane 
adhesion receptor that has a low affinity for its 
ligands in the resting state (“inactive”) and a high 
affinity in the stimulated state (“active” or 
“activated”). The affinity of integrin αIIbβ3 is 
regulated by TMD interaction of its α and β 
subunits (15) which depends on the precise tilt 
angle of the β3 TMD determined by the lipid-
protein interaction (16,17). Indeed, the 
physiological integrin-activating protein, talin (18), 
activates the integrin by altering the tilt angle of 
integrin β3 TMD (19,20). The other model 
transmembrane receptor, EGFR, normally exists in 
an inactive monomeric state and is activated upon 
ligand-induced homodimerization, in which the 
topology of its TMD may play a role (21,22). Here, 
we investigate the effect of EGCG on these two 
prototypical transmembrane signaling receptors 
and propose that EGCG can alter the membrane 
embedding of their TMDs, which in turn 
modulates transmembrane signaling by these 
receptors. 
 
RESULTS AND DISCUSSION 
 Pleiotropic effect of EGCG on activation of 
integrin αIIbβ3 – Although EGCG is reported to 
have anti-thrombotic effects (23), addition of 
EGCG to platelets, the main cellular mediators of 
arterial thrombosis, causes complex responses. For 
example, EGCG inhibited aggregation of 
thrombin-stimulated platelets, but, paradoxically, 
caused aggregation of unstimulated platelets at the 
same dose (24). To better understand the 
physiological role of this widely consumed 
polyphenol, we first tested the effect of EGCG on 
activation of recombinant integrin αIIbβ3 in 
Chinese hamster ovary (CHO) cells where the 
integrin is normally in low affinity state; with 
addition of increasing concentration of EGCG, 
there was a progressive increase in activation as 
measured by binding of PAC1, a ligand-mimetic, 
activation specific integrin αIIbβ3 antibody (25) 
(Fig. 1A, empty bars). The EGCG-induced 
increase in PAC1 binding was reduced by washing 
out EGCG (Supplemental Fig. 1), showing the 
effect is reversible and does not require the known 
oxidation-dependent reactivity toward primary 
amines (26). Physiological activation of this 
integrin requires binding of talin to the 
cytoplasmic domain of the β3 subunit (27). To ask 
whether EGCG induces physiological activation, 
we utilized a mutant αIIbβ3(Y747A) that does not 
bind talin (28). This mutant showed similar 
activation by EGCG (Fig. 1A, filled bars). Thus, 
EGCG-induced integrin activation is not 
dependent on the known intracellular signaling 
pathway. 
 To directly test the effects of EGCG on talin-
induced integrin activation, we introduced talin 
head domain (THD), the integrin activating talin 
fragment (18), into CHO cells expressing integrin 
αIIbβ3 (CHO/αIIbβ3), and examined the effects of 
EGCG on the talin-induced activation. EGCG 
blocked THD-induced αIIbβ3 activation in a dose-
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dependent manner, whereas EGCG alone induced 
integrin activation (Fig. 1B). 
 Because of complexity of cellular 
components that might mediate these paradoxical 
effects of EGCG, we utilized an in vitro 
reconstitution system in which purified integrin 
αIIbβ3 was embedded in nanodiscs, islands of 10 
nm lipid bilayer encircled by membrane scaffold 
protein (29). In the reconstituted system, addition 
of purified THD can activate the integrin (30). The 
integrin nanodiscs were first captured to the 
surface of assay plate coated with anti-integrin β3 
extracellular antibody (AP3), and the degree of 
integrin activation was measured by PAC1 binding 
to the immobilized integrin nanodiscs (Fig. 1C). 
EGCG activated the integrin nanodiscs in a dose-
dependent manner (Fig. 1C, green line), as it did in 
cells. Addition of purified THD increases PAC1 
binding in the system as previously shown (30) 
and the THD-induced increase was inhibited by 
addition of increasing amount of EGCG (Fig. 1C, 
blue line), showing a similar paradoxical effects of 
EGCG in the purified system as in cells (Fig. 1B). 
To examine the effect of EGCG on activated 
integrins in cells, we utilized αIIbβ3(D723R) 
mutant which is activated in a talin-dependent 
manner in CHO cells (28). The D723R mutation 
disrupts the electrostatic interaction between 
αIIb(R995) and β3(D723), weakening the integrin 
αIIb-β3 TMD interaction and thus favoring the 
activated state (31). The activating effect of the 
D723R mutant is dependent upon integrin-talin 
interactions, as its activation is abolished by 
disrupting integrin binding to endogenous talin, 
e.g. by the β3(Y747A) mutation (28). When we 
added EGCG to the cells expressing 
αIIbβ3(D723R), in sharp contrast to the activating 
effect observed with the wild type integrin, we 
observed that EGCG induced an initial 
suppression of activation which peaked at 200 µM 
EGCG (Fig. 2A). At higher concentration, 
however, EGCG induced activation exhibiting a 
distinct biphasic effect (Fig. 2A). Next, we tested 
another activating mutant, αIIbβ3(L712R), in 
which TMD is predicted to shorten from 29 to 19 
amino-acids due to the polar residue in the middle 
of TMD (32). The activating effect of the 
αIIbβ3(L712R) mutant is talin-independent, as its 
activation is not affected by the loss of the talin-
integrin interactions (28,33). In contrast to 
αIIbβ3(D723R), EGCG had no significant effect 
on the L712R mutant (Fig. 2B,C). 
 Opposing changes of integrin β3 TMD 
topology by EGCG and talin – To find an 
explanation for these paradoxical effects, we noted 
the insensitivity of αIIbβ3(L712R) mutant to 
EGCG. This mutant activates integrin by 
shortening the β3 TMD (32), whereas talin does it 
by increasing the lipid embedding of the β3 TMD 
(19), both of which changes can alter the β3 TMD 
tilt angle thereby disrupting the αIIb-β3 TMD 
interaction leading to integrin activation (17). In 
addition, several studies demonstrated that EGCG 
can interact with phospholipids and even can 
decrease the thickness of a lipid bilayer (9-11), 
which may alter the lipid embedding of TMDs. To 
test this idea, we investigated whether EGCG can 
change the embedding of integrin TMD by 
adapting a β3 TMD embedding assay (19). As 
EGCG had considerable spectral overlap with 
bimane, the fluorophore used in the previous study, 
we used another environment-sensitive 
fluorophore, mero60, whose fluorescence 
increases in a more hydrophobic environment and 
does not overlap with that of EGCG (34). We 
conjugated the dye to either the N-terminal end 
(β3(L694C)) or C-terminal end (β3(I721C)) of β3 
TMD and reconstituted the β3 TMD-cytoplasmic 
tail peptides into phospholipid nanodiscs (Fig. 3A). 
EGCG decreased the fluorescence of mero60 at 
either N-terminal end or C-terminal end of β3 
TMD (Fig. 3B-C), indicating that EGCG causes 
both the N and C-terminal ends of β3 TMD to 
become less embedded. The decrease in 
fluorescence is a specific result from altered 
membrane embedding of β3 TMD, as the EGCG-
induced reduction in fluorescence disappeared 
after addition of 2% SDS to disassemble the 
nanodisc (not shown). These data strongly suggest 
that EGCG reduces the embedding of the β3 TMD, 
although other mechanisms, e.g. EGCG-induced 
local unraveling of the helix, cannot be ruled out. 
Because the optimal association of integrin αIIb 
and β3 TMD depends on the precise topology of 
β3 TMD (17), our data suggest that EGCG alters 
the β3 TMD topology thereby destabilizing the α-β 
TMD association and inducing integrin activation. 
 Consistent with our previous report (19) that 
THD increases the embedding of the β3 TMD 
domain, THD increased the fluorescence 
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intensities of mero60 conjugated to β3(L694C) or 
β3(I721C) (Fig. 3D-E, black dotted lines). The 
increased fluorescence reflects an altered topology 
of the β3 TMD (19), which can also disrupt the 
association of integrin α and β TMDs. Intriguingly, 
EGCG reversed the THD-induced increase in the 
fluorescence of mero60 in both β3(L694C) and 
β3(I721C) nanodiscs (Fig. 3D-E, green dotted 
lines), indicating that EGCG alters the topology of 
the β3 TMD in a manner that opposes the effect of 
THD (Fig. 3F). We propose that EGCG-induced 
change of β3 TMD topology opposes that induced 
by talin. Thus, it can offset the talin-induced 
changes in TMD topology and integrin activation. 
The embedding assay using integrin β3 TMD 
appears more sensitive to EGCG than integrin 
activation assay. In the embedding assay, 
concentrations of EGCG from 25 µM to 100 µM 
caused large fluorescence changes both in the 
absence (Fig. 3B-C) or presence of talin (Fig. 3D-
E); whereas, higher concentrations of EGCG were 
required to affect the integrin activation assay (Fig. 
1C). This may be due to the additional stabilizing 
effect of the presence of the extracellular domains, 
which are absent in the β3 TMD embedding assays, 
on integrin αβ association and activation. 
 Effects of EGCG on transmembrane signaling 
though a receptor tyrosine kinase – If the ECGG-
induced topological change of integrin β3 TMD is 
due to an EGCG-lipid interaction, we reasoned 
EGCG should also have effects on other 
transmembrane proteins with signaling functions. 
To test this hypothesis, we focused on the receptor 
tyrosine kinases (RTKs) because the dimerization 
of their TMDs in the lipid bilayer may play a role 
in activation of those receptors (21,22). Indeed, 
EGCG was reported to inhibit activation of RTKs 
such as EGFR (35,36) possibly due to effects on 
lipid order (36). Pretreatment of HEK293 cells 
stably expressing EGFR with EGCG inhibited 
EGF-induced EGFR phosphorylation (Fig. 4A). In 
contrast, EGCG treatment in the absence of EGF 
induced EGFR phosphorylation in a 
concentration-dependent manner (Fig. 4B). 
Furthermore, EGCG decreased the fluorescence 
intensity of mero60 attached to C-terminal region 
of the nanodisc-embedded EGFR TMD (Fig. 4C). 
These data suggest that a topological change of 
EGFR TMD induced by EGF (37) can be reversed 
by the action of EGCG, and that EGCG-induced 
topological change in the absence of EGF may 
favor dimerization of EGFR TMDs leading to 
activation. 
 Our results show that EGCG can change the 
TMD topologies of receptors and activate those 
receptors. Conversely, when physiological 
activation involves shifts in TMD topology, then 
EGCG can oppose those shifts, and inhibit 
transmembrane signaling. We propose that such a 
dual effect can account for the conflicting reported 
effects of EGCG. Recent studies showed that 
EGCG can bind to lipid bilayers and reside near 
the phosphate head groups of phospholipids, and 
that the interaction is further stabilized by cation-π 
interaction between one of the ring structures in 
EGCG and quaternary amine of the phospholipid 
head group (8). Because the interactions between 
TMDs and phospholipids can influence the 
topology of TMDs in a lipid bilayer by 
mechanisms such as snorkeling of the basic lysine 
side chain into the phosphate head groups of the 
phospholipids (16), EGCG may alter the 
interaction of the TMD with the phosphate head 
group thus leading to changes in TMD topology. 
Alternatively, the rigidity of lipids induced by 
insertion of EGCG into hydrophobic lipid bilayer 
as suggested by molecular simulation study (38), 
or the rigidity of lipid-inserted EGCG itself due to 
its less flexible aromatic rings, might alter the tilt 
angle of TMDs causing less embedding. Future 
studies will be required to address these 
hypotheses; however, our observation that EGCG 
has a dual effect on transmembrane signaling by 
modulating lipid embedding of TMDs provides an 
attractive mechanism to explain some of EGCG's 
pleiotropic effects on transmembrane signaling. 
 
EXPERIMENTAL PROCEDURES 
 Reagents, cell lines, and plasmids – 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) 
and 1,2-dimyristoyl-sn-glycero-3-phospho-(1’-rac-
glycerol) (DMPG) were purchased from Avanti 
Polar Lipids, Inc. Membrane scaffold protein 
(MSP1D1) was kindly provided by Dr. Steven 
Sligar (University of Illinois at Urbana-
Champaign). PAC1 and D57 were described 
previously (16). Anti-FLAG antibody (M2) and 
Anti-phosphotyrosine antibody (4G10) were 
purchased from Sigma-Aldrich and Merck 
Millipore, respectively. CHO/αIIb and 
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CHO/αIIbβ3 cells were generated by infecting 
CHO cells with lentivirus encoding αIIb and/or β3 
as previously described (16). HEK/EGFR cells 
were kindly provided by Dr. Seung-Taek Lee 
(Yonsei University). The β3 TMD-tail fused with 
N-terminal 6xHis and ketosteroid isomerase (KSI) 
in the pET-31 expression vector was described 
previously (19). Similarly, the EGFR TMD 
(Pro637 ~ Gln701) construct containing N-
terminal 6xHis and KSI with cysteine mutation at 
Phe667 was generated by ligation of the PCR-
amplified EGFR TMD region into the pET-31 
expression vector. 
 Flow cytometry – Transfection and flow 
cytometry were performed with a similar 
procedure as described before (23). Briefly, CHO 
or CHO/αIIb cells were transfected with various 
integrin constructs using Lipofectamine LTX and 
Plus reagents (Life Technologies) or 
Lipofectamine 2000 (Life Technologies). 
CHO/αIIbβ3 cells were transfected with total of 10 
µg plasmids which include 1 µg tdTomato cDNA 
as a transfection marker. At 24 h after transfection, 
cells were detached by trypsinization and treated 
with EGCG for 10 min. Those cells were stained 
with PAC1 followed by allophycocyanin-
conjugated anti–mouse IgM antibody. When 
integrin constructs were transfected, cells were co-
stained with D57 to gate cells with similar high 
αIIbβ3 expression.  
 EGFR phosphorylation assay – Serum-
starved subconfluent HEK/EGFR cells were 
treated with varying concentration of EGCG for 
30 min before EGF treatment (final 50 ng/ml). 
Cells were lysed by a lysis buffer (20 mM HEPES, 
pH 7.4, 150 mM NaCl, 1% Triton X-100, 10 mM 
EDTA, pH 7.4, supplemented with PhosStop 
(Roche) and protease inhibitor cocktail (Roche)). 
After clarification by centrifugation at 17,000 g for 
30 min, the clarified lysates were incubated at 4°C 
overnight in the presence of 3 µg anti-FLAG 
antibody and the bound proteins were precipitated 
with protein G sepharose. The bound proteins 
were analyzed by SDS-PAGE and subsequent 
western blot with anti-phosphotyrosine antibody 
and anti-EGFR antibody. 
 Expression and purification of TMD peptides 
– The preparation of integrin nanodiscs was 
performed essentially as previously described (19). 
Briefly, 6xHis-KSI fused TMD proteins were 
expressed in E.coli BL21(DE3) and purified using 
HiTrap Chelating HP column charged with Ni2+. 
The Asp-Pro bond between KSI and TMD peptide 
in the purified TMD proteins was cleaved in 10% 
formic acid for 120 mins at 80 °C (24). The 
resulting TMD peptide was then dialyzed against a 
buffer containing 50 mM Tris-HCl, pH 7.4, 500 
mM NaCl, and 6 M urea, and then passed through 
a Ni2+-NTA column again to absorb the KSI, 
leaving the purified TMD peptide in the solution. 
The TMD peptide was labeled with excess mero60 
(1:5 molar ratio). 0.1 % Triton X-100 was added to 
the labeled TMD peptide and the labeled TMD 
peptide was then dialyzed extensively against 0.1 % 
Triton X-100 in Tris-buffered saline (TBS, 20 mM 
Tris-HCl, pH 7.4, 150 mM NaCl). 
 Preparation of integrin nanodiscs – The 
preparation of integrin nanodiscs was previously 
described (25). Briefly, DMPC and DMPG lipids 
were dissolved in chloroform or 
chloroform/methanol mixture, mixed into 1:1 ratio, 
and dried onto a glass tube with steady flow of 
argon. The lipid mixture was dissolved in 100 mM 
cholate in TBS. To assemble nanodiscs, 360 μl of 
the 1:1 lipid mixture (50 mM), 1 ml of 200 μM 
MSP1D1, and the purified TMD peptides (10 μM) 
or the purified integrin αIIbβ3 from human 
platelets (10 μM) were mixed. The mixture was 
added with two volumes of Biobeads SM-2 (Bio-
Rad) to initiate nanodisc assembly and incubated 
overnight at room temperature in the dark. The 
assembled nanodiscs were further purified with a 
size exclusion column (hi-load 16/60 Superdex 
200) with TBS as the column buffer. When 
necessary, the nanodiscs were concentrated using 
Ultracel-30k (Millipore). 
 Fluorescence spectroscopy – 200 μl of the 
purified nanodiscs were mixed with 50 μl of 
various concentrations or EGCG (and THD in the 
case of β3 TMD nanodiscs). After 30 min of 
incubation at room temperature, the emission 
spectrum (from 605 nm to 655 nm) at the 
excitation wavelength, 593 nm, was scanned with 
1 nm interval using FluoroMax-2 
Spectrofluorometer (Instruments S.A., Inc.). The 
fluorescence from unlabeled TMD peptide, talin, 
empty nanodiscs, or buffer was negligible. The 
fluorescence of the samples was re-measured after 
addition of 2% SDS (final concentration). 
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FIGURE LEGENDS 
 
FIGURE 1. EGCG both activates and inhibits activation of integrin αIIbβ3 in cells and a 
reconstituted system.  
(A) CHO cells stably expressing integrin αIIb were transfected with wild type or talin binding-deficient 
mutant (Y747A) integrin β3. EGCG-treated cells with comparable αIIbβ3 expression (high D57 staining) 
were gated and the degree of integrin activation of these gated cells was measured by PAC1, an activation 
specific integrin αIIbβ3 antibody. Specific PAC1 binding was calculated as MFI-MFI0, where MFI is the 
mean fluorescence intensity of bound PAC1 and MFI0 is that in the presence of 10 mM EDTA or 20 μM 
eptifibatide both of which inhibit integrin αIIbβ3-ligand binding. (B) CHO cells stably expressing αIIbβ3 
were transfected with empty vector or talin head domain (THD) together with tdTomato cDNA as a 
transfection marker. Specific PAC1 binding of tdTomato positive cells treated with different concentration 
of EGCG was calculated and shown as described in (A). (C) The configuration of the integrin nanodisc 
activation assay is shown. Integrin nanodiscs were captured on to an ELISA plate coated with anti-β3 
antibody (AP3). Specific PAC1 binding was calculated as L-L0, where L is PAC1 binding to the captured 
integrin nanodisc measured by chemiluminescence and L0 is that in the presence of eptifibatide. The 
effects of EGCG on specific PAC1 binding were measured in the absence (green line) or presence of 
purified THD (10 µM) (blue line). Throughout the panels, error bars represent standard errors (n=3), and 
ANOVA multiple comparison using the Bonferroni’s test was performed to test for significant differences 
between EGCG-treated and non-treated samples. **P<0.01, ***P<0.001, ****P<0.0001. 
 
FIGURE 2. EGCG has distinct effects on talin-dependent and talin-independent αIIbβ3 activation.  
(A-B) CHO cells were transfected with integrin αIIb and activating β3 mutants, β3(D727R) (talin-
dependent) or β3(L712R) (talin-independent), and specific PAC1 binding was measured as described in 
Fig. 1A. (C) % inhibition of integrin activation was calculated as 100 x (P0-P)/P0, where P0 is the specific 
PAC1 binding in the absence of EGCG and P is that in the presence of EGCG. Note that EGCG initially 
inhibits and then increases activation of the talin-dependent αIIbβ3(D723R) mutant whereas it does not 
inhibit the talin-independent αIIbβ3(L712R) mutant. Error bars represent standard errors (n=3). 
****P<0.0001. 
  
FIGURE 3. EGCG alters β3 TMD topological changes in the opposite direction to talin. (A) The 
environment-sensitive dye, mero60, was conjugated to β3 TMD-tail peptide through the cysteine mutation 
at Leu694 residue to probe the embedding change of β3 TMD at the outer membrane leaflet or at Ile721 
residue at the inner membrane leaflet. The mero60-labeled β3 TMD peptides were then incorporated into 
phospholipid nanodiscs. (B) EGCG decreases the fluorescence intensity of L694C-mero60 nanodiscs. 
EGCG is not fluorescent at the wavelength range measured in the analysis. Fluorescence intensities were 
normalized to the maximum fluorescence intensity in the mero60-β3-TMD nanodiscs without EGCG. (C) 
The fluorescence of I721C-mero60 nanodiscs were analyzed as in (B). (D) Mero60-β3(L694C) nanodiscs 
were incubated with 10 µM THD with or without EGCG. EGCG reverses the increase of mero60 
fluorescence intensity induced by THD. (E) The effect of EGCG on mero60-β3(I721C) nanodiscs were 
analyzed as in (D). (F) Proposed model of EGCG's action. Because the association of integrin αIIb and β3 
TMD depends on the precise tilt angle of β3 TMD, either increased or decreased embedding of the β3 
TMD can disrupt the α-β TMD association and activate the integrin. Talin binding to integrin β3 tail 
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increases the TMD tilt angle, thereby activating integrin. EGCG interacts with the phospholipid bilayer 
and reduces the integrin TMD tilting angle. When both effects are present, EGCG first neutralizes the 
effect of talin but continued reduction in the tilt angle by EGCG activates the integrin. 
 
FIGURE 4. EGCG has a dual effect on EGFR signaling. (A) HEK293 cells expressing FLAG-tagged 
human EGFR (HEK/EGFR) were serum-starved overnight and pretreated with different concentration of 
EGCG. 30 min after EGCG treatment, cells were stimulated with 50 ng/ml EGF for additional 30 min. 
EGFR was immunoprecipitated and analyzed with anti-phosphotyrosine antibody and anti-EGFR 
antibody. The degree of phosphotyrosine signal per precipitated EGFR band intensities were normalized 
to un-stimulated control (0%) and EGF-treated control (100%), and shown as bar graph for each sample. 
Error bars represent standard errors (n=3). Representative western blots are shown below. (B) 
Phosphorylation of unstimulated EGFR in the presence of different concentration of EGCG was analyzed 
as in (A). EGCG induced EGFR phosphorylation in a dose-dependent manner. Error bars represent 
standard errors (n=3). For panels A and B, one way ANOVA multiple comparison using the Bonferroni’s 
test was performed to test for significant differences between EGCG-treated and non-treated samples. 
*P<0.05, ****P<0.0001. (C) Effects of EGCG on lipid embedding of EGFR TMD. Left, Purified EGFR 
TMD peptide (EGFR(F667C)) labeled with mero60 was reconstituted into nanodiscs, and the effect of 
EGCG on the embedding of EGFR TMD was analyzed as in Fig. 3B. Right, EGCG has little effect on 
mero60 fluorescence when EGFR TMD nanodiscs were solubilized with 2% SDS.  
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